Molecular target identification, also known as target deconvolution, is an essential part of the drug discovery process for understanding a compound’s mechanism of action and further optimizing a series of chemical matter.

View our webinar to learn how capture compound mass spectrometry (CCMS), an industry-leading chemoproteomics platform, surpasses traditional target deconvolution methods, allowing us to identify specific-binding protein targets for small molecules, achieving not only target deconvolution, but novel target identification and off-target profiling as well.


  • Sam Mann, PhD, Principal Scientist, Charles River
  • Will Stebbeds, PhD, Senior Scientist, Charles River